Abbott Reports 12% Growth in Device Sales

Abbott Laboratories(NYSE:ABT) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of $1.26, an 11% increase compared to the prior year and a 16% rise compared to the first quarter. Management reaffirmed its view of 2025 as a transition year marked by transient headwinds -- primarily in diagnostics -- while affirming a commitment to high single-digit percentage organic sales growth and double-digit non-GAAP EPS expansion amid robust margin gains.Revenues from the company's medical devices segment grew 12% in the quarter, fueled by double-digit gains in diabetes care, heart failure, electrophysiology, and rhythm management, with continuous glucose monitor sales reaching $1.9 billion (up 19.5%). The launch of the Volt PFA catheter and the completion of enrollment in the PACIFLEX DUO US trial reflected its rapid innovation cadence in the electrophysiology indication.These milestones underscore an agile R&D model that rapidly iterates and commercializes next-generation technologies, fortifying Abbott Laboratories' long-term position in high-growth and high-barrier medtech categories.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool